Loading…
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug–drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical...
Saved in:
Published in: | Clinical pharmacokinetics 2019-06, Vol.58 (6), p.727-746 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3 |
container_end_page | 746 |
container_issue | 6 |
container_start_page | 727 |
container_title | Clinical pharmacokinetics |
container_volume | 58 |
creator | Miller, Neil A. Reddy, Micaela B. Heikkinen, Aki T. Lukacova, Viera Parrott, Neil |
description | Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug–drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical applications, and new regulatory impact is expected as its full power is leveraged. As one example, physiologically based pharmacokinetic modelling is already routinely used during drug discovery for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species, and this leads to the application of verified models for first-in-human pharmacokinetic predictions. A consistent cross-industry strategy in this application area would increase confidence in the approach and facilitate further learning. With this in mind, this article aims to enhance a previously published first-in-human physiologically based pharmacokinetic model-building strategy. Based on the experience of scientists from multiple companies participating in the GastroPlus™ User Group Steering Committee, new Absorption, Distribution, Metabolism and Excretion knowledge is integrated and decision trees proposed for each essential component of a first-in-human prediction. We have reviewed many relevant scientific publications to identify new findings and highlight gaps that need to be addressed. Finally, four industry case studies for more challenging compounds illustrate and highlight key components of the strategy. |
doi_str_mv | 10.1007/s40262-019-00741-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2259822436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2259822436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3</originalsourceid><addsrcrecordid>eNp9kc2OFCEUhYnROO3oC7gwJK5RLtQf7mY6jtPJGDvRWRMKqGpGGlqoiqkH8j2lu0fduYFc7jnfITkIvQb6Diht3-eKsoYRCoKUsQIinqAVQCsICNY8RSvKgZFaNPwCvcj5gVLaMUqfowtOWya4aFfo13a3ZBd9HJ1W3i_4WmVr8Han0l7p-N0FOzmNP0djvXdhxENM-MalPJFNILfzXgW8TdY4PbkY8gd8FfD9waipQE4mfD07b47Or1Mqz-OCN97P-TQY_NNNO7zelWgbxqNqE8xxueB1-UjxzMbZ_BI9G5TP9tXjfYnubz5-W9-Suy-fNuurO6IrEBNh1aC5YaKDmnOhOhjazljb9A0XYBWUg_eDZhVTAENt9NConoPtTVsAdc8v0dsz95Dij9nmST7EOYUSKRmrRcdYxZuiYmeVTjHnZAd5SG6v0iKBymMz8tyMLM3IUzNSFNObR_Tc7635a_lTRRHwsyCXVRht-pf9H-xvd_6coQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2259822436</pqid></control><display><type>article</type><title>Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies</title><source>Nexis UK</source><source>Springer Nature</source><creator>Miller, Neil A. ; Reddy, Micaela B. ; Heikkinen, Aki T. ; Lukacova, Viera ; Parrott, Neil</creator><creatorcontrib>Miller, Neil A. ; Reddy, Micaela B. ; Heikkinen, Aki T. ; Lukacova, Viera ; Parrott, Neil</creatorcontrib><description>Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug–drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical applications, and new regulatory impact is expected as its full power is leveraged. As one example, physiologically based pharmacokinetic modelling is already routinely used during drug discovery for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species, and this leads to the application of verified models for first-in-human pharmacokinetic predictions. A consistent cross-industry strategy in this application area would increase confidence in the approach and facilitate further learning. With this in mind, this article aims to enhance a previously published first-in-human physiologically based pharmacokinetic model-building strategy. Based on the experience of scientists from multiple companies participating in the GastroPlus™ User Group Steering Committee, new Absorption, Distribution, Metabolism and Excretion knowledge is integrated and decision trees proposed for each essential component of a first-in-human prediction. We have reviewed many relevant scientific publications to identify new findings and highlight gaps that need to be addressed. Finally, four industry case studies for more challenging compounds illustrate and highlight key components of the strategy.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.1007/s40262-019-00741-9</identifier><identifier>PMID: 30729397</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Decision trees ; Internal Medicine ; Knowledge ; Medicine ; Medicine & Public Health ; Metabolism ; Pharmaceutical industry ; Pharmaceuticals ; Pharmacokinetics ; Pharmacology/Toxicology ; Pharmacotherapy ; Physiology ; Review Article</subject><ispartof>Clinical pharmacokinetics, 2019-06, Vol.58 (6), p.727-746</ispartof><rights>The Author(s) 2019</rights><rights>Copyright Springer Nature B.V. Jun 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3</citedby><cites>FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3</cites><orcidid>0000-0003-3077-5790</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30729397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, Neil A.</creatorcontrib><creatorcontrib>Reddy, Micaela B.</creatorcontrib><creatorcontrib>Heikkinen, Aki T.</creatorcontrib><creatorcontrib>Lukacova, Viera</creatorcontrib><creatorcontrib>Parrott, Neil</creatorcontrib><title>Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><addtitle>Clin Pharmacokinet</addtitle><description>Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug–drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical applications, and new regulatory impact is expected as its full power is leveraged. As one example, physiologically based pharmacokinetic modelling is already routinely used during drug discovery for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species, and this leads to the application of verified models for first-in-human pharmacokinetic predictions. A consistent cross-industry strategy in this application area would increase confidence in the approach and facilitate further learning. With this in mind, this article aims to enhance a previously published first-in-human physiologically based pharmacokinetic model-building strategy. Based on the experience of scientists from multiple companies participating in the GastroPlus™ User Group Steering Committee, new Absorption, Distribution, Metabolism and Excretion knowledge is integrated and decision trees proposed for each essential component of a first-in-human prediction. We have reviewed many relevant scientific publications to identify new findings and highlight gaps that need to be addressed. Finally, four industry case studies for more challenging compounds illustrate and highlight key components of the strategy.</description><subject>Decision trees</subject><subject>Internal Medicine</subject><subject>Knowledge</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Pharmacokinetics</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Physiology</subject><subject>Review Article</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc2OFCEUhYnROO3oC7gwJK5RLtQf7mY6jtPJGDvRWRMKqGpGGlqoiqkH8j2lu0fduYFc7jnfITkIvQb6Diht3-eKsoYRCoKUsQIinqAVQCsICNY8RSvKgZFaNPwCvcj5gVLaMUqfowtOWya4aFfo13a3ZBd9HJ1W3i_4WmVr8Han0l7p-N0FOzmNP0djvXdhxENM-MalPJFNILfzXgW8TdY4PbkY8gd8FfD9waipQE4mfD07b47Or1Mqz-OCN97P-TQY_NNNO7zelWgbxqNqE8xxueB1-UjxzMbZ_BI9G5TP9tXjfYnubz5-W9-Suy-fNuurO6IrEBNh1aC5YaKDmnOhOhjazljb9A0XYBWUg_eDZhVTAENt9NConoPtTVsAdc8v0dsz95Dij9nmST7EOYUSKRmrRcdYxZuiYmeVTjHnZAd5SG6v0iKBymMz8tyMLM3IUzNSFNObR_Tc7635a_lTRRHwsyCXVRht-pf9H-xvd_6coQ</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Miller, Neil A.</creator><creator>Reddy, Micaela B.</creator><creator>Heikkinen, Aki T.</creator><creator>Lukacova, Viera</creator><creator>Parrott, Neil</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0003-3077-5790</orcidid></search><sort><creationdate>20190601</creationdate><title>Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies</title><author>Miller, Neil A. ; Reddy, Micaela B. ; Heikkinen, Aki T. ; Lukacova, Viera ; Parrott, Neil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Decision trees</topic><topic>Internal Medicine</topic><topic>Knowledge</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Pharmacokinetics</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Physiology</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, Neil A.</creatorcontrib><creatorcontrib>Reddy, Micaela B.</creatorcontrib><creatorcontrib>Heikkinen, Aki T.</creatorcontrib><creatorcontrib>Lukacova, Viera</creatorcontrib><creatorcontrib>Parrott, Neil</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, Neil A.</au><au>Reddy, Micaela B.</au><au>Heikkinen, Aki T.</au><au>Lukacova, Viera</au><au>Parrott, Neil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies</atitle><jtitle>Clinical pharmacokinetics</jtitle><stitle>Clin Pharmacokinet</stitle><addtitle>Clin Pharmacokinet</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>58</volume><issue>6</issue><spage>727</spage><epage>746</epage><pages>727-746</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><abstract>Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug–drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical applications, and new regulatory impact is expected as its full power is leveraged. As one example, physiologically based pharmacokinetic modelling is already routinely used during drug discovery for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species, and this leads to the application of verified models for first-in-human pharmacokinetic predictions. A consistent cross-industry strategy in this application area would increase confidence in the approach and facilitate further learning. With this in mind, this article aims to enhance a previously published first-in-human physiologically based pharmacokinetic model-building strategy. Based on the experience of scientists from multiple companies participating in the GastroPlus™ User Group Steering Committee, new Absorption, Distribution, Metabolism and Excretion knowledge is integrated and decision trees proposed for each essential component of a first-in-human prediction. We have reviewed many relevant scientific publications to identify new findings and highlight gaps that need to be addressed. Finally, four industry case studies for more challenging compounds illustrate and highlight key components of the strategy.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30729397</pmid><doi>10.1007/s40262-019-00741-9</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0003-3077-5790</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0312-5963 |
ispartof | Clinical pharmacokinetics, 2019-06, Vol.58 (6), p.727-746 |
issn | 0312-5963 1179-1926 |
language | eng |
recordid | cdi_proquest_journals_2259822436 |
source | Nexis UK; Springer Nature |
subjects | Decision trees Internal Medicine Knowledge Medicine Medicine & Public Health Metabolism Pharmaceutical industry Pharmaceuticals Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Physiology Review Article |
title | Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T05%3A01%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physiologically%20Based%20Pharmacokinetic%20Modelling%20for%20First-In-Human%20Predictions:%20An%20Updated%20Model%20Building%20Strategy%20Illustrated%20with%20Challenging%20Industry%20Case%20Studies&rft.jtitle=Clinical%20pharmacokinetics&rft.au=Miller,%20Neil%20A.&rft.date=2019-06-01&rft.volume=58&rft.issue=6&rft.spage=727&rft.epage=746&rft.pages=727-746&rft.issn=0312-5963&rft.eissn=1179-1926&rft_id=info:doi/10.1007/s40262-019-00741-9&rft_dat=%3Cproquest_cross%3E2259822436%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c419t-24fc3d29815339a81f78dee6b6391ea191e3bfc242a11f5dcf6ab31ebd7c415b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2259822436&rft_id=info:pmid/30729397&rfr_iscdi=true |